Evolving R&D Paradigms and Intellectual Property Strategies: A Historical Analysis across the Chemical, Biological, and Information Paradigms (original) (raw)
Related papers
PICMET '07 - 2007 Portland International Conference on Management of Engineering & Technology, 2007
As research in biology transitions from the chemical, to the biological paradigm, and now to the information-based (systems biology) paradigm, researchers should be aware of how such a transition is likely to interact with the existing patent regime. Such interactions critically affect investments in research and decisions relating to when to patent and what to patent. Practicing researchers both in the biological sciences and other scientific disciplines are increasingly facing the need to develop research and exploitation strategies in domains that are dynamic and complex. The traditional research addressing patent thickets and patent pools offers insufficient guidance with respect to new biological knowledge structures and their accompanying challenges.
Recent decades have seen some intense debates concerning the alleged wholesale misappropriation of traditional knowledge by the pharmaceutical industry. As this article demonstrate, both of the extreme views, that traditional knowledge substantially subsidises the pharmaceutical industry, and that traditional knowledge has no relevance for present and future drug discovery, are incorrect. The article also investigates the question of whether, as is so often alleged, patents allow and legitimate the misappropriation of traditional knowledge. Doubtless, the occasional inefficiencies of prior art searches and examinations for inventive step have led to the grant of patents claiming traditional knowledge. But this article seeks to look beyond this problem to see whether patent systems are so biased epistemologically that the mere translation of traditional knowledge into the “language”of modern professional science is sufficient for grant of a patent.
Ownership of knowledge--the role of patents in pharmaceutical R&D
Bulletin of The World Health Organization, 2004
Both the public and the private sectors contribute to research and development (R&D) in pharmaceuticals. The public sector originates many of the discoveries of new drugs. The private sector, which focuses on development, is heavily reliant on patents. Though patents are presumed to reward genuine inventions, lax rules on patentability and shortcomings in procedures permit protection to be obtained on a myriad of minor developments. These patents, though weak and possibly invalid in many cases, are used to restrain competition and delay the entry of generic competition. Developing countries should design and implement their patent laws so as to prevent strategic patenting and promote competition and access to medicines.
BioLaw Journal, 2021
During the last two decades, the genomics revolution has contributed enormously to the development of novel research approaches in the field of biological sciences. We have seen the development of new biotechnological tools capable of modifying organisms in order to perform specific tasks designing and assembling novel biological components. All these scientific and biotechnological innovations present also a substantial challenge for the law and especially for intellectual property rights. In particular – as a consequence of relevant patent case law in the United States and Europe affecting precision medicine – the debate on the possible future of biotech patents gained increasing momentum. Considering this multifaceted scenario, the purpose of this article is to analyse the impact of various judicial decisions with respect to patents subject-matter eligibility and the prosecution of biotech-related patent applications.
Patents and New Product Development in the Pharmaceutical and Biotechnology Industries
This paper examines the rationale for intellectual property protection in the development of new pharmaceutical products. Prior survey studies of R&D executives have found that patents play a more critical role in appropriating the benefits of innovation in pharmaceuticals compared to other high tech industries. This paper considers why this is so based on an analysis of the economic characteristics of R&D costs and returns in the pharmaceutical and biotechnology industries. The final section examines recent policy developments and issues surrounding patent lifetime and generic competition in this industry. The pharmaceutical and biotechnology industries, which are among the most research intensive industries, have been the focus of several benefit cost and social return on R&D studies. Elsewhere in this symposium, Frank Lichtenberg has reported on his finding concerning the impact of new drugs on increased longevity, worker productivity, and savings in other types of medical expenditures. 4 He finds significant aggregate net benefits to society from new drug introductions. His analysis is consistent with more microeconomic analyses targeted to specific medical conditions such as cardiovascular disease, depression, and infectious disease. These studies have also found high incremental social benefits from new drug innovation. 5 Another general finding of the academic literature is that public policy actions can have a significant influence on the rate of innovation in particular industries. Among the key industrial policies influencing the innovative process in pharmaceuticals are the public support of biomedical research, patents, FDA regulatory policy, and government reimbursement controls. 6 The focus of this paper is on the role and impact of patents and intellectual property protection in the discovery and development of new pharmaceutical and biotechnical products. The importance of patents to pharmaceutical innovation has been reported in several cross-industry studies by economists. In particular, Richard Levin, et al, and Wes Cohen, et al, have undertaken surveys of U.S. R&D managers in a large cross-section of 4
On the Challenges Facing Patent Pooling in Biotechnology
SSRN Electronic Journal, 2013
The role of patent law and patent practice especially in biotech has gained considerable attention of late as there are concerns that innovative efforts are stifled rather than fostered by intellectual property in the area. In this article, the authors survey some of the difficulties encountered in biotech when it comes to innovation and discuss aspects that touch on the efficacy of patent pooling to overcome innovation barriers. In light of a review of the related research literature addressing the area, it is found that analogies to other industries and areas of R&D are not insightful. As a result, it is concluded that further empirical research and theoretical modeling of patent pooling in biotechnology are needed in order to establish sound policy recommendations.